Health Canada approves first generic semaglutide injection for weight loss: what it means for Canadian patients

This article is for informational purposes only and is not medical advice. Consult your Canadian healthcare provider about your situation.

Health Canada authorized Svemia, a once-weekly generic semaglutide (sold in Canada under the brand name Wegovy by Novo Nordisk) injection produced by Canadian pharmaceutical company Apotex, for chronic weight management in people aged 12 and older on June 30, 2026, making Canada the first G7 country to approve a generic semaglutide product for weight loss. For Canadians who have been paying out of pocket for Wegovy or going without it entirely because of cost, this approval opens the door to a potentially far cheaper version of the same active molecule, though how much cheaper and how quickly it reaches pharmacy shelves depends on decisions that have not yet been made.

Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist, a class of drugs that mimics a gut hormone to reduce appetite and slow gastric emptying. Wegovy, the brand-name version approved for weight management, has carried a monthly cost of roughly CAD $350 to $500 for most Canadian patients paying privately. Health Canada states that generic medications in Canada are typically priced between 45 and 90 per cent below their brand-name equivalents, which would place Svemia somewhere between roughly CAD $50 and $275 per month if that range holds. No list price for Svemia has been published as of July 1, 2026.

What this means in Canada

Health Canada confirmed the Svemia authorization on June 30, 2026, after determining that Apotex's submission met the department's standards for safety, efficacy, and quality for generic drugs. Health Canada also noted it is reviewing six additional generic semaglutide submissions from other manufacturers and expects further regulatory decisions in the coming weeks and months. A separate Apotex generic semaglutide product for adults with Type 2 diabetes was authorized by Health Canada on May 1, 2026.

On the coverage side, the picture is incomplete. Wegovy is not currently listed on most provincial formularies for weight management. Ontario's OHIP drug benefit program (the Ontario Drug Benefit), Quebec's RAMQ, British Columbia's PharmaCare, and Alberta's AHCIP drug benefit have not publicly announced plans to add Svemia or any generic semaglutide for obesity to their covered drug lists. The federal Canadian Drug Agency (formerly CADTH) would typically conduct a health technology assessment before provinces consider formulary listing, and no such assessment for generic semaglutide for weight management has been published as of this writing. Patients in provinces with income-based pharmacare programs should not assume coverage will follow automatically from Health Canada approval.

The Society of Obstetricians and Gynaecologists of Canada (SOGC) has not issued a position statement specifically on generic semaglutide for weight management. The Obesity Canada clinical practice guidelines, published in 2020 and updated in subsequent years, support GLP-1 receptor agonists as a treatment option for obesity when diet and physical activity alone are insufficient, but those guidelines address the drug class broadly and predate the generic approval.

Canadian telehealth platforms including Felix, a Canadian men's and women's health platform, and Science & Humans (scienceandhumans.com), a Canadian hormone and metabolic health service, have been prescribing brand-name semaglutide where clinically appropriate. US-only platforms such as Hone Health and Midi do not serve Canadian patients. Whether Canadian platforms will be able to offer Svemia at lower cost depends on when Apotex brings the product to market and at what price.

What changed

Before this approval, Canadians seeking semaglutide for weight loss had one option at the pharmacy: Wegovy, at brand-name prices. Generic competition has a documented track record of reducing drug costs in Canada. The federal government's Patented Medicine Prices Review Board and provincial formulary negotiations have historically relied on generic entry to bring prices down, and Health Canada's own statement cited lower costs for patients and the health-care system as an anticipated benefit.

The timing also matters geopolitically. Health Canada's May 2026 announcement described Canada as the first G7 country to approve a generic semaglutide product, which positions Canadian patients ahead of their counterparts in the United States, the United Kingdom, Germany, France, Italy, and Japan in terms of regulatory access. The US FDA has not yet approved a generic semaglutide injection for weight management as of July 1, 2026.

Apotex is a Toronto-based company and one of the largest generic pharmaceutical manufacturers in the world. Its involvement means domestic manufacturing capacity may be part of the supply picture, though Apotex has not publicly confirmed Canadian production for Svemia specifically.

What Canadian patients should know

Health Canada authorization means Svemia has cleared the regulatory bar for safety, efficacy, and quality. It does not mean the drug is available at your pharmacy today. Generic drugs require a period of commercial launch after authorization, and Apotex has not announced a retail availability date.

If you are currently taking Wegovy and your prescriber or pharmacist suggests switching to Svemia once available, Health Canada's generic drug framework requires that the two products be pharmaceutically equivalent, meaning the active ingredient, dose, and route of administration are the same. Differences in non-medicinal ingredients (fillers, preservatives, device components) are assessed to confirm they do not affect safety or effectiveness.

Patients in Ontario, Quebec, British Columbia, and Alberta should contact their provincial drug benefit program or a pharmacist to ask whether Svemia will be listed and under what conditions. Patients with private insurance should check their plan formulary, as private insurers often add generics more quickly than provincial programs once a product is commercially available.

For patients who cannot afford Wegovy now and are waiting for a lower-cost option, the authorization is a meaningful step, but it is not yet a solution. Ask your prescriber whether you qualify for any existing manufacturer patient-support programs for Wegovy in the interim, and watch for Apotex's commercial launch announcement.

Semaglutide is approved for chronic weight management as a supplement to a reduced-calorie diet and increased physical activity, not as a standalone treatment. The approved indication for Svemia covers people aged 12 and older, the same population covered by Wegovy's Canadian authorization.

Limitations and open questions

Several things are not yet known. Apotex has not announced a retail price or a launch date for Svemia. No provincial pharmacare program has committed to listing it. Health Canada has not published the full product monograph for Svemia in a form accessible to the public as of July 1, 2026. The six additional generic semaglutide submissions under review could further increase competition and drive prices lower, but timelines for those decisions have not been specified.

Longer-term, the cardiovascular and metabolic outcome data underpinning semaglutide's clinical profile come from trials of the brand-name product. Generic bioequivalence standards confirm that the drug behaves the same way in the body at the same dose, but no independent long-term outcome trials of Svemia specifically have been conducted or are planned, which is standard practice for generics and not a safety concern per se, but worth understanding.

The SOGC has not commented on this approval. Obesity Canada has not yet updated its clinical guidance to address generic availability. The Canadian Medical Association Journal (CMAJ) has not published a clinical review of the generic approval as of this writing.

Patients and clinicians should watch for updates from Health Canada's drug product database, provincial formulary announcements, and Apotex's commercial communications over the coming months.

This article is for informational purposes only and is not medical advice. Consult your Canadian healthcare provider about your situation.

Editorial note

Hormone Journal articles are written by our editorial team and reviewed against published clinical guidelines, with a focus on Canadian patient access. We do not promote specific clinics or providers.